Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients With Tumors Harboring Actionable NTRK Fusions
Sponsor: National Cancer Institute (NCI)
Listed as NCT03213704, this observational or N/A phase trial focuses on Advanced Malignant Solid Neoplasm and Recurrent Ependymoma and remains ongoing. Sponsored by National Cancer Institute (NCI), it has been updated 90 times since 2017, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Study Description(click to expand)PRIMARY OBJECTIVE: I. To determine the objective response rate (ORR; complete response + partial response) in pediatric patients treated with larotrectinib sulfate (LOXO-101 \[larotrectinib\]) with advanced solid tumors (including central nervous system \[CNS\] tumors), non-Hodgkin lymphomas or histiocytic disorders harboring NTRK 1/2/3 fusions. SECONDARY OBJECTIVES: I. To estimate the progression free survival in pediatric patients treated with LOXO-101 (larotrectinib) with advanced solid tumors (including CNS tumors), non-Hodgkin lymphomas or histiocytic disorders with NTRK 1/2/3 fusions. II. To obtain additional information about the tolerability of LOXO-101 (larotrectinib) in children with relapsed or refractory cancer. III. To provide preliminary estimates of the pharmacokinetics of LOXO-101 (larotrectinib) in children with relapsed or refractory cancer. EXPLORATORY OBJECTIVE: I. To explore approaches to profiling changes in tumor genomics over time through evaluation of circulating tumor deoxyribonucleic acid (DNA). OUTLINE: Patients receive larotrectinib sulfate orally (PO) or via nasogastric (NG)- or gastric (G)-tube twice per day (BID) on days 1-28. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo a computed tomography (CT) scan, magnetic resonance imaging (MRI), an x-ray, bone scan, and/or iobenguane (MIBG) scintigraphy during screening and on study. Patients also undergo...
PRIMARY OBJECTIVE:
I. To determine the objective response rate (ORR; complete response + partial response) in pediatric patients treated with larotrectinib sulfate (LOXO-101 \[larotrectinib\]) with advanced solid tumors (including central nervous system \[CNS\] tumors), non-Hodgkin lymphomas or histiocytic disorders harboring NTRK 1/2/3 fusions.
SECONDARY OBJECTIVES:
I. To estimate the progression free survival in pediatric patients treated with LOXO-101 (larotrectinib) with advanced solid tumors (including CNS tumors), non-Hodgkin lymphomas or histiocytic disorders with NTRK 1/2/3 fusions.
II. To obtain additional information about the tolerability of LOXO-101 (larotrectinib) in children with relapsed or refractory cancer.
III. To provide preliminary estimates of the pharmacokinetics of LOXO-101 (larotrectinib) in children with relapsed or refractory cancer.
EXPLORATORY OBJECTIVE:
I. To explore approaches to profiling changes in tumor genomics over time through evaluation of circulating tumor deoxyribonucleic acid (DNA).
OUTLINE:
Patients receive larotrectinib sulfate orally (PO) or via nasogastric (NG)- or gastric (G)-tube twice per day (BID) on days 1-28. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo a computed tomography (CT) scan, magnetic resonance imaging (MRI), an x-ray, bone scan, and/or iobenguane (MIBG) scintigraphy during screening and on study. Patients also undergo bone marrow aspiration and/or biopsy during screening and may undergo blood sample collection on study.
After completion of study treatment, patients are followed up at 30 days, then periodically thereafter.
Status Flow
Change History
90 versions recorded-
Apr 28, 2026 — Present [daily]
Active Not Recruiting
Phase: PHASE2 → None
-
Jan 2026 — Apr 2026 [monthly]
Active Not Recruiting PHASE2
-
Dec 2025 — Jan 2026 [monthly]
Active Not Recruiting PHASE2
-
Nov 2025 — Dec 2025 [monthly]
Active Not Recruiting PHASE2
-
Sep 2025 — Nov 2025 [monthly]
Active Not Recruiting PHASE2
▶ Show 85 earlier versions
-
Aug 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE2
-
Jun 2025 — Aug 2025 [monthly]
Active Not Recruiting PHASE2
-
Mar 2025 — Jun 2025 [monthly]
Active Not Recruiting PHASE2
-
Dec 2024 — Mar 2025 [monthly]
Active Not Recruiting PHASE2
-
Nov 2024 — Dec 2024 [monthly]
Active Not Recruiting PHASE2
-
Oct 2024 — Nov 2024 [monthly]
Active Not Recruiting PHASE2
-
Sep 2024 — Oct 2024 [monthly]
Active Not Recruiting PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Aug 2024 [monthly]
Active Not Recruiting PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
-
Apr 2024 — Jun 2024 [monthly]
Active Not Recruiting PHASE2
-
Feb 2024 — Apr 2024 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jan 2024 — Feb 2024 [monthly]
Recruiting PHASE2
-
Nov 2023 — Jan 2024 [monthly]
Recruiting PHASE2
-
Oct 2023 — Nov 2023 [monthly]
Recruiting PHASE2
-
Sep 2023 — Oct 2023 [monthly]
Recruiting PHASE2
-
Aug 2023 — Sep 2023 [monthly]
Recruiting PHASE2
-
Jul 2023 — Aug 2023 [monthly]
Recruiting PHASE2
-
Jun 2023 — Jul 2023 [monthly]
Recruiting PHASE2
-
May 2023 — Jun 2023 [monthly]
Recruiting PHASE2
-
Apr 2023 — May 2023 [monthly]
Recruiting PHASE2
-
Mar 2023 — Apr 2023 [monthly]
Recruiting PHASE2
-
Feb 2023 — Mar 2023 [monthly]
Recruiting PHASE2
-
Jan 2023 — Feb 2023 [monthly]
Recruiting PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Recruiting PHASE2
-
Nov 2022 — Dec 2022 [monthly]
Recruiting PHASE2
-
Oct 2022 — Nov 2022 [monthly]
Recruiting PHASE2
-
Sep 2022 — Oct 2022 [monthly]
Recruiting PHASE2
-
Jul 2022 — Sep 2022 [monthly]
Recruiting PHASE2
-
Jun 2022 — Jul 2022 [monthly]
Recruiting PHASE2
-
May 2022 — Jun 2022 [monthly]
Recruiting PHASE2
-
Apr 2022 — May 2022 [monthly]
Recruiting PHASE2
-
Mar 2022 — Apr 2022 [monthly]
Recruiting PHASE2
-
Feb 2022 — Mar 2022 [monthly]
Recruiting PHASE2
-
Jan 2022 — Feb 2022 [monthly]
Recruiting PHASE2
-
Dec 2021 — Jan 2022 [monthly]
Recruiting PHASE2
-
Nov 2021 — Dec 2021 [monthly]
Recruiting PHASE2
-
Oct 2021 — Nov 2021 [monthly]
Recruiting PHASE2
-
Sep 2021 — Oct 2021 [monthly]
Recruiting PHASE2
-
Jun 2021 — Sep 2021 [monthly]
Recruiting PHASE2
-
May 2021 — Jun 2021 [monthly]
Recruiting PHASE2
-
Apr 2021 — May 2021 [monthly]
Recruiting PHASE2
-
Mar 2021 — Apr 2021 [monthly]
Recruiting PHASE2
-
Feb 2021 — Mar 2021 [monthly]
Recruiting PHASE2
-
Jan 2021 — Feb 2021 [monthly]
Recruiting PHASE2
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Nov 2020 — Dec 2020 [monthly]
Recruiting PHASE2
-
Oct 2020 — Nov 2020 [monthly]
Recruiting PHASE2
-
Aug 2020 — Oct 2020 [monthly]
Recruiting PHASE2
-
Jul 2020 — Aug 2020 [monthly]
Recruiting PHASE2
-
Jun 2020 — Jul 2020 [monthly]
Recruiting PHASE2
-
May 2020 — Jun 2020 [monthly]
Recruiting PHASE2
-
Apr 2020 — May 2020 [monthly]
Recruiting PHASE2
-
Mar 2020 — Apr 2020 [monthly]
Recruiting PHASE2
-
Feb 2020 — Mar 2020 [monthly]
Recruiting PHASE2
-
Jan 2020 — Feb 2020 [monthly]
Recruiting PHASE2
-
Dec 2019 — Jan 2020 [monthly]
Recruiting PHASE2
-
Nov 2019 — Dec 2019 [monthly]
Recruiting PHASE2
-
Oct 2019 — Nov 2019 [monthly]
Recruiting PHASE2
-
Sep 2019 — Oct 2019 [monthly]
Recruiting PHASE2
-
Aug 2019 — Sep 2019 [monthly]
Recruiting PHASE2
-
Jul 2019 — Aug 2019 [monthly]
Recruiting PHASE2
-
Jun 2019 — Jul 2019 [monthly]
Recruiting PHASE2
-
May 2019 — Jun 2019 [monthly]
Recruiting PHASE2
-
Apr 2019 — May 2019 [monthly]
Recruiting PHASE2
-
Mar 2019 — Apr 2019 [monthly]
Recruiting PHASE2
-
Feb 2019 — Mar 2019 [monthly]
Recruiting PHASE2
-
Jan 2019 — Feb 2019 [monthly]
Recruiting PHASE2
-
Dec 2018 — Jan 2019 [monthly]
Recruiting PHASE2
-
Nov 2018 — Dec 2018 [monthly]
Recruiting PHASE2
-
Oct 2018 — Nov 2018 [monthly]
Recruiting PHASE2
-
Sep 2018 — Oct 2018 [monthly]
Recruiting PHASE2
-
Aug 2018 — Sep 2018 [monthly]
Recruiting PHASE2
-
Jul 2018 — Aug 2018 [monthly]
Recruiting PHASE2
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE2
-
May 2018 — Jun 2018 [monthly]
Recruiting PHASE2
-
Apr 2018 — May 2018 [monthly]
Recruiting PHASE2
-
Mar 2018 — Apr 2018 [monthly]
Recruiting PHASE2
-
Feb 2018 — Mar 2018 [monthly]
Recruiting PHASE2
-
Jan 2018 — Feb 2018 [monthly]
Recruiting PHASE2
-
Dec 2017 — Jan 2018 [monthly]
Recruiting PHASE2
-
Nov 2017 — Dec 2017 [monthly]
Recruiting PHASE2
-
Oct 2017 — Nov 2017 [monthly]
Recruiting PHASE2
-
Sep 2017 — Oct 2017 [monthly]
Recruiting PHASE2
-
Aug 2017 — Sep 2017 [monthly]
Recruiting PHASE2
First recorded
Eligibility Summary
This phase II Pediatric MATCH trial studies how well larotrectinib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with NTRK fusions that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) and have come back (relapased) or does not respond to treatment (refractory). Larotrectinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Contact Information
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .